Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Konopleva, M; Hogge, DE; Rizzieri, DA; Cirrito, TP; Liu, JS; Kornblau, SM; Grable, M; Hwang, I-R; Borthakur, G; Mankin, A; Bivins, C; Garcia-Manero, G; Kadia, T; Harris, D; Ravandi, F; Andreeff, M; Cortes, JE; Niecestro, R; Bergstein, I; Kantarjian, HM; Frankel, AE

Published Date

  • November 19, 2010

Published In

Volume / Issue

  • 116 / 21

Start / End Page

  • 1351 - 1351

Published By


  • 1

International Standard Serial Number (ISSN)

  • 0006-4971

Conference Name

  • 52nd Annual Meeting of the American-Society-of-Hematology (ASH)

Conference Location

  • Orlando, FL

Conference Start Date

  • December 4, 2010

Conference End Date

  • December 7, 2010